[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,296,311
  • Shares Outstanding, K 171,236
  • Annual Sales, $ 1,072 M
  • Annual Income, $ 391,000 K
  • EBIT $ 81 M
  • EBITDA $ 87 M
  • 60-Month Beta 0.80
  • Price/Sales 4.09
  • Price/Cash Flow 28.86
  • Price/Book 3.51

Options Overview Details

View History
  • Implied Volatility 56.69% (+3.70%)
  • Historical Volatility 30.83%
  • IV Percentile 73%
  • IV Rank 34.83%
  • IV High 98.54% on 01/09/26
  • IV Low 34.32% on 12/30/25
  • Expected Move (DTE 31) 1.16 (4.58%)
  • Put/Call Vol Ratio 0.36
  • Today's Volume 38
  • Volume Avg (30-Day) 333
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 9,016
  • Open Int (30-Day) 8,887
  • Expected Range 24.10 to 26.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.05
  • Number of Estimates 7
  • High Estimate $0.12
  • Low Estimate $-0.01
  • Prior Year $0.16
  • Growth Rate Est. (year over year) -68.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.59 +17.25%
on 06/22/26
27.31 -7.31%
on 06/26/26
+3.69 (+17.09%)
since 06/18/26
3-Month
20.30 +24.70%
on 05/19/26
27.31 -7.31%
on 06/26/26
+3.52 (+16.12%)
since 04/21/26
52-Week
19.69 +28.57%
on 10/13/25
28.35 -10.71%
on 12/23/25
+3.03 (+13.62%)
since 07/21/25

Most Recent Stories

More News
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies ...

ACAD : 25.26 (+0.68%)
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time

ACAD : 25.26 (+0.68%)
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

-- Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth

ACAD : 25.26 (+0.68%)
Stock Indexes Finish Lower as Chipmakers Sell Off

The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -0.05%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.09%. September...

SNDK : 1,567.62 (+12.70%)
STX : 898.73 (+12.00%)
WDC : 550.56 (+12.95%)
SPY : 748.52 (+0.87%)
ADSK : 212.97 (-2.22%)
MU : 977.79 (+12.98%)
QMCO : 11.67 (+6.19%)
NUTX : 169.80 (+5.16%)
QQQ : 710.03 (+2.01%)
FTNT : 157.10 (-2.03%)
NOW : 101.96 (-2.62%)
ADBE : 226.73 (-3.41%)
Stock Indexes Slip as Chipmakers Retreat

The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.75%. September E-mini S&P futures...

AMAT : 568.42 (+8.13%)
AVGO : 386.08 (+2.09%)
SNDK : 1,567.62 (+12.70%)
INTU : 290.58 (-1.10%)
DDOG : 254.65 (-3.25%)
TXN : 293.97 (+3.49%)
$IUXX : 29,180.50 (+2.01%)
ASML : 1,806.58 (+3.88%)
ZNU26 : 108-200 (-0.22%)
MSFT : 398.91 (-0.84%)
ESU26 : 7,548.75 (+0.86%)
STX : 898.73 (+12.00%)
Stocks Pressured by Weakness in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is down -0.54%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.38%. September E-mini S&P futures...

AMAT : 568.42 (+8.13%)
SNDK : 1,567.62 (+12.70%)
INTU : 290.58 (-1.10%)
DDOG : 254.65 (-3.25%)
TXN : 293.97 (+3.49%)
$IUXX : 29,180.50 (+2.01%)
ASML : 1,806.58 (+3.88%)
ZNU26 : 108-200 (-0.22%)
ESU26 : 7,548.75 (+0.86%)
STX : 898.73 (+12.00%)
WDC : 550.56 (+12.95%)
LRCX : 321.68 (+4.86%)
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

-- European Commission decision expected in the coming months -- If approved, DAYBU ® would become the first treatment for neurobehavioral symptoms...

ACAD : 25.26 (+0.68%)
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide...

ACAD : 25.26 (+0.68%)
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according...

ACAD : 25.26 (+0.68%)
Acadia: Q1 Earnings Snapshot

Acadia: Q1 Earnings Snapshot

ACAD : 25.26 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 26.95
2nd Resistance Point 26.56
1st Resistance Point 25.82
Last Price 25.26
1st Support Level 24.69
2nd Support Level 24.30
3rd Support Level 23.56

See More

52-Week High 28.35
Last Price 25.26
Fibonacci 61.8% 25.04
Fibonacci 50% 24.02
Fibonacci 38.2% 23.00
52-Week Low 19.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.